Revolution Medicines, Inc.

Revolution Medicines announced it will present new data from its RAS(ON) pipeline at the 2026 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress. The presentations include two oral presentations from Phase 1/2 trials evaluating zoldonrasib in combination regimens for metastatic RAS G12D pancreatic ductal adenocarcinoma (PDAC). Additionally, two Phase 3 trials-in-progress posters for daraxonrasib in PDAC will be featured, highlighting its potential as a monotherapy or in combination for first-line treatment and as an adjuvant therapy.

Revolution Medicines announced that Dr. Steve Kelsey, President of Research and Development, will retire effective January 4, 2027, transitioning to a new role as Senior Advisor to the CEO on July 1, 2026. The company also held its Annual Meeting, where stockholders elected two Class III directors, ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm, and approved executive compensation on a non-binding, advisory basis.

Revolution Medicines announced detailed positive results from the global, randomized Phase 3 RASolute 302 clinical trial evaluating daraxonrasib in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). The oral RAS(ON) multi-selective inhibitor demonstrated unprecedented improvements in overall survival (OS) and progression-free survival (PFS) compared to standard of care chemotherapy, meeting all primary and key secondary endpoints. Daraxonrasib also showed a manageable safety profile and significantly delayed deterioration in cancer-related pain, global health status, and quality of life. The company plans to submit these data to global regulatory authorities, including the U.S. FDA.

Revolution Medicines announced that its senior management team will host a webcast on Sunday, May 31, at 7:00 pm ET. The webcast will discuss positive results from the Phase 3 RASolute 302 clinical trial, which evaluated daraxonrasib in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). These data are scheduled for presentation during the Plenary Session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

Revolution Medicines announced that The New England Journal of Medicine (NEJM) published data from its Phase 1/2 clinical trial evaluating daraxonrasib, a RAS(ON) multi-selective inhibitor, in patients with previously treated metastatic RAS mutant pancreatic ductal adenocarcinoma (PDAC). These promising findings supported the initiation of the company’s global, randomized Phase 3 registrational trial, RASolute 302, which recently announced positive topline results showing an unprecedented overall survival benefit. Daraxonrasib demonstrated promising clinical antitumor activity, durable responses, and an acceptable safety profile. The drug has received FDA Breakthrough Therapy and Orphan Drug Designations and is being evaluated in multiple Phase 3 trials.

Revolution Medicines reported a significant increase in net loss to $(453.8) million for Q1 2026, up from $(213.4) million in Q1 2025, primarily due to higher research and development and general and administrative expenses. To support its operations, the company raised $226.7 million in net proceeds through at-the-market equity offerings during the quarter, including initiating a new $1 billion ATM program. Despite an accumulated deficit of $3.3 billion, management expects existing capital to fund operations for at least 12 months.

Revolution Medicines announced positive Phase 3 RASolute 302 trial results for daraxonrasib in metastatic pancreatic cancer, demonstrating an unprecedented survival benefit with a median OS of 13.2 months. These data will be submitted to global regulatory authorities, including the U.S. FDA. The company also reported a strengthened financial position with $2.2 billion in gross proceeds from recent financings and provided its Q1 2026 financial results, including a net loss of $453.8 million.

Revolution Medicines, Inc. (RVMD) filed its definitive proxy statement (DEF 14A) for its 2026 Annual Meeting of Stockholders. The meeting will be held online on June 18, 2026, at 7:30 a.m. Pacific Time. Stockholders will vote on the election of two Class III directors, the ratification of PricewaterhouseCoopers LLP as the independent auditor, and an advisory vote on executive compensation.

Revolution Medicines announced updated Phase 1/2 clinical data for daraxonrasib in previously untreated metastatic pancreatic cancer, showing promising results for both monotherapy and combination with chemotherapy. The daraxonrasib plus gemcitabine and nab-paclitaxel (GnP) combination achieved a 58% objective response rate and 84% 6-month progression-free survival in 40 patients. The data supports continued evaluation in the first-line setting, including the ongoing Phase 3 RASolute 303 trial, indicating potential for a novel RAS-targeted therapy.

Revolution Medicines announced promising preclinical data for a new class of mutant-targeted catalytic RAS(ON) inhibitors. These inhibitors, exemplified by RM-055, are designed to convert active mutant RAS to an inactive state, mimicking physiological regulation. Preclinical studies showed RM-055 drove deep and durable tumor regressions across various KRAS G12 mutant xenograft models, notably overcoming resistance to existing RAS inhibitors. This novel mechanism aims to address tumor resistance and extend the durability of current RAS-targeted therapies.